Cyclacel Pharmaceuticals To Present Clinical Data At 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib's Potential As A Precision Medicine For Cancer
Cyclacel Pharmaceuticals To Present Clinical Data At 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib's Potential As A Precision Medicine For Cancer
- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma -
- 新型CDK2/9抑制剂fadraciclib单药治疗研究中的临床、PK和PD数据支持进行中的概念证明研究，该研究针对实体肿瘤和淋巴瘤患者 -
BERKELEY HEIGHTS, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that new clinical, pharmacokinetic (PK) and pharmacodynamic (PD) data from the CYC065-101 study of fadraciclib as oral monotherapy was presented at a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago, IL. See link to poster here.
2024年6月3日，新泽西州伯克利高地（GLOBE NEWSWIRE）——生物制药公司Cyclacel Pharmaceuticals, Inc.（纳斯达克:CYCC,纳斯达克:CYCCP，“Cyclacel”或“公司”），开发基于癌细胞生物学的创新药物，今天宣布，CYC065-101研究的fadraciclib作为口服单一疗法的新临床、药代动力学（PK）和药效学（PD）数据已于2024年5月31日至6月4日的美国临床肿瘤学会（ASCO）年会上作为展板展示，地点位于伊利诺伊州芝加哥。点击这里查看海报。